Trials / Completed
CompletedNCT05658471
Pharmacokinetics and Pharmacodynamics of Nicotine With Use of Standardized Research Electronic Cigarette (SREC)
Comparative Pharmacokinetics and Pharmacodynamics of Nicotine With Use of NIDA Standardized Research Electronic Cigarette (SREC) vs Usual Brand E-cigarette
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- University of California, San Francisco · Academic / Other
- Sex
- All
- Age
- 21 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
This is a crossover study that will examine use behaviors, chemical exposures, and biological effects of Standardized Research Electronic Cigarette (SREC) compared to usual brand e-cigarette use in natural or synthetic nicotine users.
Detailed description
OBJECTIVES: I. To characterize nicotine delivery, systemic exposure and effects from SREC in comparison with usual to usual nicotine brand use. II. To assess aspects of harm of SREC use compared to usual nicotine brand use. OUTLINE: Eligible participants will be assigned to one of two treatment conditions for the initial assessment which will take place in a hospital setting. The participant will then be assigned to the second condition within 2 weeks after the initial assessment which will also take place in a hospital setting to repeat the same procedures.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Standardized Research E-Cigarette (SREC) | Standardized Research E-Cigarette (SREC) will be obtained through NJOY, LLC and provided at the hospital stay. |
| OTHER | Over the Counter E-Cigarette (EC) | Usual brand e-cigarettes will be provided at the hospital stay. |
| BEHAVIORAL | Biological Samples | Blood, urine, and expired carbon dioxide will be obtained during the course of the study. |
| OTHER | Smoking-related Questionnaires | Nicotine and Smoking behavior and dependence questionnaires will be administered at screening, before and during hospital stays. |
Timeline
- Start date
- 2023-02-01
- Primary completion
- 2026-01-31
- Completion
- 2026-01-31
- First posted
- 2022-12-20
- Last updated
- 2026-03-27
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT05658471. Inclusion in this directory is not an endorsement.